Company news

Minerva Neurosciences, Inc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia

September 29, 2021

Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research & Development

September 7, 2021

Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates

August 1, 2021

Minerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates

May 11, 2021

Minerva Neurosciences Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Following the Completion of the 40-Week Open-Label Extension

May 10, 2021

Minerva Neurosciences Reports Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates

March 7, 2021

Minerva Neurosciences to Report Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates on March 8, 2021

February 28, 2021

Minerva Neurosciences and Royalty Pharma Announce Sale of Seltorexant Royalty for up to $155 Million

January 18, 2021

Minerva Neurosciences Announces Outcome of Type C Meeting with FDA and Next Steps in the Development of Roluperidone

November 30, 2020

Minerva Neurosciences Reports Third Quarter 2020 Financial Results And Business Updates

November 1, 2020

Minerva Neurosciences to Report Third Quarter 2020 Financial Results and Business Updates on November 2, 2020

October 25, 2020

Minerva Neurosciences Reports Second Quarter 2020 Financial Results and Business Updates

August 2, 2020

Minerva Neurosciences Exercises Right to Opt Out of Agreement With Janssen for Seltorexant (MIN-202)

June 30, 2020

REVISED WEBCAST & CALL INFORMATION: Minerva Neurosciences to Hold Webcast and Call With Key Opinion Leaders to Present Additional Analyses From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia

May 31, 2020

Minerva Neurosciences Announces Results From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia

May 28, 2020

Minerva Neurosciences Reports First Quarter 2020 Financial Results and Business Updates

May 3, 2020

Minerva Neurosciences Reports Fiscal 2019 Fourth Quarter and Year End Financial Results and Business Updates

March 8, 2020

Minerva Neurosciences to Report Fiscal 2019 Fourth Quarter and Year End Financial Results and Business Updates on March 9, 2020

March 1, 2020

Minerva Neurosciences Announces Completion of Patient Enrollment in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

February 4, 2020

Minerva Neurosciences Announces Completion of Patient Screening in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

January 5, 2020

Minerva Neurosciences Reports Topline Results From Phase 2b Trial of MIN-117 in Major Depressive Disorder

December 17, 2019

Minerva Neurosciences Reports Third Quarter 2019 Financial Results and Business Updates

November 3, 2019

Minerva Neurosciences Announces Update for Three Clinical Trials

September 30, 2019

Minerva Neurosciences to Host Conference Call and Live Webcast on Tuesday, October 1 at 8: 30 AM ET

September 25, 2019

← Newer news releases

Calls

The 5 newest of 11 calls. Every call is listed under its year.

Decks

The 5 newest of 20 decks. Every deck is listed under its year.